Related Experiment Videos
Rapamycin in lung transplantation
R Laporta Hernández1, P Ussetti Gil, C García Gallo
1Lung Transplant Unit, Clínica Puerta de Hierro, Madrid, Spain. roslaporta@arsytel.com
Transplantation Proceedings
|January 3, 2006
Summary
Rapamycin (RAPA) can stabilize or improve lung function in lung transplant recipients with bronchiolitis obliterans (BOS). Close monitoring for adverse effects, particularly infections, is crucial during RAPA treatment.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Bronchiolitis obliterans (BOS) is a significant complication in lung transplant recipients.
- Rapamycin (RAPA) possesses immunosuppressive and antiproliferative properties, suggesting potential therapeutic value in BOS.
- This study investigates RAPA's efficacy in patients with refractory BOS.
Purpose of the Study:
- To evaluate the effectiveness of Rapamycin (RAPA) in lung transplant recipients with bronchiolitis obliterans (BOS).
- To assess changes in pulmonary function and identify adverse events associated with RAPA treatment in BOS patients.
Main Methods:
- Retrospective analysis of 11 lung transplant recipients with BOS treated with RAPA.
- Evaluation of clinical characteristics, pulmonary function (FEV1), and complications.
- RAPA was administered in conjunction with calcineurin inhibitors and steroids.
Main Results:
- 72% of patients (8/11) demonstrated improved or stabilized FEV1 after RAPA initiation.
- Common adverse effects included infections (6/12) and myelosuppression (3/11).
- Treatment withdrawal due to adverse effects occurred in 2 patients.
Conclusions:
- Rapamycin (RAPA) may stabilize or improve pulmonary function in lung transplant recipients with BOS.
- Close patient monitoring is essential to detect and manage potential adverse effects, especially infections.